Cannabis cultivator and research firm Biolife Group has acquired a 20% stake in AHA Corporate, a group of companies offering support services to healthcare providers.
BioLife has a cultivation facility in Byron Bay and two in Thailand (Bangkok and Chiang Rai) alongside its research division.
AHA and wholly owned subsidiaries Alliance Healthcare Australia, CuratD Health, Chronic Doctors, ScriptIT, Chemist Greenhouse and 5LEAF offer support services to healthcare providers including access to discounts, rebates, technology systems, business analytics, and operations.
The company specialises in integrating medicinal cannabis into traditional pharmacy settings.
Biolife and AHA said the investment “completes the creation of a unique, vertically integrated business model that aims to revolutionise support services and profit margins for healthcare providers across Australia”.
“This partnership brings together expertise in healthcare, pharmaceuticals, cutting-edge medicinal cannabis solutions and cultivation to provide comprehensive support to healthcare providers,” they added.
Biolife COO Patrick Mauder described the acquisition as a “game-changer” for both companies.
“By combining our strengths, we are uniquely positioned to provide healthcare providers with the resources they need to navigate the evolving landscape of medicinal cannabis,” he said.
“Our vertically integrated approach ensures that we can deliver high-quality products and services efficiently and effectively.”
AHA CEO Brendon Rose added: “We are thrilled to welcome Biolife Group as a strategic partner. Their investment underscores the potential of our integrated business model and our commitment to supporting healthcare providers across Australia.
“Together, we are setting a new standard for the incorporation of medicinal cannabis into traditional pharmacy practices.”
